'Expanding universe of alternatives'
Willis Towers Watson to oversee whole strategy
2016 model portfolio underperformed benchmark
Which trusts were analyst favourites for the year?
Will appoint investment managers by February
Biotech sector not the only beneficiary
Needs to 'remain relevant' to shareholders
Discount narrowed significantly
Say Electra faces 12 months of uncertainty